How can organ chips empower drug development and disease research under the driving force of FDA's new policies?-Chemical Instrument Network

Heavy Forecast

Is it difficult to predict human reactions through animal experiments?

High investment in drug development but low success rate?

Is the experimental data difficult to replicate and meet regulatory requirements?

Under the new policies of global regulatory agencies such as the FDA, organ chips are becoming an important tool to replace some animal experiments and improve the predictability of drug development.

This time, we bring you a 3-hour high-density live broadcast focusing on microfluidic and organ chip applications:

Under the FDA Roadmap: Organ Chips Empower Drug Development and Disease Research

September 24, 2025 (next Wednesday) 13:30-16:35

Xiao'e Tong live streaming platform, scan the code to make an appointment directly

点成直播 | FDA新政驱动下，器官芯片如何赋能药物研发与疾病研究？

Who is this live broadcast suitable for?

If you are from:

1. Pharmaceutical and biotechnology companies (drug discovery, preclinical research, toxicology, pharmacology departments)

2. Frontier academic laboratories in universities/research institutes (organ chips, organoids, tumors, nerves, nanomedicine delivery)

3. Clinical translational and diagnostic development institutions (tertiary hospital translational medicine center, IVD company)

And care about the following issues

How to use organ chips to reduce animal experiments and improve the success rate of new drug development?

How to achieve standardized and reproducible experimental procedures in microfluidics?

How to obtain high connotation cell phenotype data to support new drug decision-making?

4. What are the real application prospects of organoids and disease models under the FDA's new policy?

So, this live stream is tailor-made for you!

Four keynote speeches | Focusing on core pain points and cutting-edge practices

From the forefront of scientific research to business decision-making: the dual value and implementation path of organ chips under global regulatory changes | Luo Chencheng | Diancheng Biotechnology Engineer

Organ corepieceA 10-year technological roadmap for replacing human drug experiments | Peng Xingyue | Professor at Xiamen University

The practical application of FDA's new policy and 3-step completion 1-bond formed organoids in drug development | Han Xinxin | Founder and CEO of Dr. Lisheng Biotechnology

Beyond Static Cultivation: A New Paradigm for Building Dynamic Human Thrombosis Models on Chips | Tony Palu | Cellix Ireland

Heavy guest lineup

点成直播 | FDA新政驱动下，器官芯片如何赋能药物研发与疾病研究？

Point into Biology

Diancheng Biotechnology is a company specializing in one-stop solutions for the fields of biology and medicine (formerly known as Hongke Biotechnology Division). Supported by more than a decade of technological accumulation and customer base in the fields of medicine, biology, and healthcare, we focus on providing one-stop solutions for pharmaceutical companies, biotechnology companies, medical institutions, universities, and research institutions, serving from basic research to sample analysis, and the entire lifecycle of drugs to ensure quality and safety.

The main business scope covers: pharmaceutical supply chain environmental monitoring, temperature verification, life science instruments, laboratory equipment, medical equipment, and GxP compliance consulting and services.

We have deep and long-term technical cooperation with world-class multinational corporations and instrument manufacturing centers, committed to providing customers with innovative solutions. By continuously innovating and providing professional services, we help our clients ensure accurate, reliable, and 100% compliant monitoring, validation, and experimentation processes. Our clients include companies and institutions such as Roche, Pfizer, Sanofi, Baxter, Lanzhou Biotech, Sinovac, Fosun Pharma, Lonza, BeiGene, WuXi AppTec, West China Hospital, Xiangya Hospital, Peking University, Tsinghua University, etc.

We are committed to safeguarding the quality and safety of drugs and the development of biotechnology, promoting the development of the healthcare industry, and facilitating the realization of a world with highly developed drug safety and medical technology.